PowerPoint: CSID in Pediatrics

Important Safety Information for Sucraid^® (sacrosidase) Oral Solution

• Sucraid^® may cause a serious allergic reaction. Patients should stop taking Sucraid^® and get emergency help immediately if any of the following side effects occur: difficulty breathing, wheezing, or swelling of the face. Care should be taken when administering initial doses of Sucraid^® to observe any signs of acute hypersensitivity reaction.
• Do not use Sucraid^® with patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol).
• Although Sucraid^® provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase.
• Adverse reactions as a result of taking Sucraid^® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
• Before prescribing Sucraid^® to diabetic patients, the physician should consider that Sucraid® will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose.
• The effects of Sucraid^® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
• DO NOT HEAT SOLUTIONS CONTAINING SUCRAID^®. Do not put Sucraid^® in warm or hot fluids. Do not reconstitute or consume Sucraid^® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid^®. Half of the reconstituted Sucraid^® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
• Sucraid^® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light; single-use containers can be removed from refrigeration and stored at 59°F-77°F (15°C-25°C) for up to 3 days (72 hours).

Indication

Sucraid^® (sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of Congenital Sucrase-Isomaltase Deficiency (CSID).